Silence Therapeutics (SLN) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Silence Therapeutics (SLN).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 420K (+1300.00%) | 30K (-81.25%) | 160K (-27.27%) | 220K (+57.14%) | 140K (-99.45%) | 25M (+1587.33%) | 1.50M (+97.37%) | 760K (-95.16%) | 16M |
Gross Profit | 410K (+1950.00%) | 20K (-80.00%) | 100K (-28.57%) | 140K (+55.56%) | 90K (-99.61%) | 23M | -2.14M (-17.05%) | -2.58M | 13M |
Operating Expenses | |||||||||
Research And Development | 9.12M (+4.23%) | 8.75M (-57.40%) | 21M (+16.37%) | 18M (-15.19%) | 21M (-5.75%) | 22M (+9.52%) | 20M (+46.09%) | 14M (+16.46%) | 12M |
Selling General And Administrative | 7.03M (+88.47%) | 3.73M (-35.69%) | 5.80M (+13.06%) | 5.13M (-33.20%) | 7.68M (+38.63%) | 5.54M (-28.05%) | 7.70M (+9.84%) | 7.01M (+5.57%) | 6.64M |
Operating Expenses | 16M (+29.41%) | 12M (-52.62%) | 26M (+15.63%) | 23M (-20.07%) | 29M (+3.19%) | 28M (-0.86%) | 28M (+33.88%) | 21M (+12.61%) | 18M |
Depreciation And Amortization | 70K (-70.83%) | 240K | - | - | 70K (-72.00%) | 250K | - | - | 90K |
Operating Income | |||||||||
Operating Income | -15.74M (+26.32%) | -12.46M (-52.52%) | -26.24M (+9.52%) | -23.96M (-15.66%) | -28.41M (+553.10%) | -4.35M (-85.50%) | -30.00M (+28.26%) | -23.39M (+319.18%) | -5.58M |
Ebit | -15.74M (+26.32%) | -12.46M (-52.52%) | -26.24M (+9.52%) | -23.96M (-15.66%) | -28.41M (+553.10%) | -4.35M (-85.50%) | -30.00M (+28.26%) | -23.39M (+319.18%) | -5.58M |
EBITDA | -15.66M (+10.83%) | -14.13M (-32.59%) | -20.96M (-23.34%) | -27.34M (-3.53%) | -28.34M (+1047.37%) | -2.47M (-93.04%) | -35.49M (+81.72%) | -19.53M (+255.74%) | -5.49M |
Net Income | |||||||||
Income Before Tax | -14.96M (+27.10%) | -11.77M (-43.85%) | -20.96M (-23.34%) | -27.34M (-4.17%) | -28.53M | 13M | -35.49M (+81.72%) | -19.53M (+843.48%) | -2.07M |
Income Tax Expense | - | - | - | 10K | - | 320K (+540.00%) | 50K (-78.26%) | 230K (-4.17%) | 240K |
Net Income From Continuing Operations | -14.96M (+27.10%) | -11.77M (-43.85%) | -20.96M (-23.36%) | -27.35M (-4.14%) | -28.53M | 12M | -35.54M (+79.95%) | -19.75M (+754.98%) | -2.31M |
Net Income | -14.96M (+27.10%) | -11.77M (-43.85%) | -20.96M (-23.36%) | -27.35M (-4.14%) | -28.53M | 12M | -35.54M (+79.95%) | -19.75M (+754.98%) | -2.31M |
Comprehensive Income Net Of Tax | -15.35M (-80.77%) | -79.81M (+252.67%) | -22.63M (+9.48%) | -20.67M (-16.75%) | -24.83M (-46.44%) | -46.36M (+66.34%) | -27.87M (+42.41%) | -19.57M (+725.74%) | -2.37M |